| Withdrawn | N/A | 130 | NA | Standard anti-emetics in conjunction with R-CHOP, R-CHOP:, rituximab, doxorubicin, vincristine, cyclophosphamide, prednisolone, Anti-emetics:, ondansetron, granisetron, tropisetron, palonosetron, metoclopramide, prochlorperazine, lorazepam, aprepitant | Australasian Leukaemia and Lymphoma Group, Merck Sharp & Dohme LLC | Lymphoma, Non-Hodgkin | 06/15 | 06/15 | | |
NCT05974410: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients |
|
|
| Available | N/A | | NA | AVM0703, Hydrocortisone, Proton pump inhibitor | AVM Biotechnology Inc | Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Breast Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Acute Leukemia, Pancreatic Cancer, Spindle Cell Sarcoma, Cancer, Tumor, Solid, Tumor, Brain, Esophageal Andeocarcinoma, Mixed Phenotype AML, Desmoplastic Round Cell Sarcoma | | | | |
